One-year Trastuzumab treatment is recommended for all HER2-positive breast cancer patients, but clinical benefits from extended treatment of Trastuzumab seem to be limited, partially due to the acquired resistance [6–9]. This evidence concerns the gene ERBB2 and breast cancer.